Drug Trial Radar · NCT03665207
Tight Versus Liberal Blood Glucose Control in Adult Critically Ill Patients
Last checked: Nov 20, 2026Latest source record: Jun 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
9,230
Actual
Start
Sep 18, 2018
Primary completion
Nov 30, 2022
Study completion Nov 2026
Sponsor
- Lead sponsor
- KU LeuvenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Universitaire Ziekenhuizen KU Leuven; Research Foundation Flanders
- First posted
- Sep 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Critically ill patients usually develop hyperglycemia, which is associated with an increased risk of morbidity and mortality. Controversy exists on whether targeting normal blood glucose concentrations with insulin therapy, referred to as tight blood glucose control (TGC) improves outcome of these patients, as compared to tolerating hyperglycemia. It remains unknown whether TGC, when applied with optimal tools to avoid hypoglycemia, is beneficial in a context of withholding early parenteral nutrition. The TGC-fast study hypothesizes that TGC is beneficial in adult critically ill patients not receiving early parenteral nutrition, as compared to tolerating hyperglycemia.
Conditions
- Critical Illness
- Hyperglycemia
Interventions
InsulinDrug
When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of ICU dependencyTime frame: up to 1 year after randomization
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Department of Intensive Care Medicine, University Hospital Ghent
Ghent, Belgium
Department of Intensive Care Medicine, Jessa Hospital Hasselt
Hasselt, Belgium
Department of Intensive Care Medicine, University Hospitals Leuven
Leuven, Belgium
Medical Intensive Care Unit, University Hospitals Leuven
Leuven, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.